Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
| General Information of Drug (ID: DR2227) | ||||||
|---|---|---|---|---|---|---|
| Drug Name |
R-5495
|
|||||
| Synonyms |
D-Ribopyranose; D-Ribopyranoside; D-Ribose; D-Ribose, 99.0%+; R-5495; Ribopyranose; Ribopyranoside; Ribose; SCHEMBL339948; SRBFZHDQGSBBOR-SOOFDHNKSA-N; (3R,4R,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol; (3R,4R,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol; 10257-32-6; C21057; CHEBI:47006; CTK0H1736; D-Rib; DTXSID70450356; EC 700-481-3; Rib; D-ribose
|
|||||
| Indication | Congestive heart failure [ICD11: BD10] | Phase 2 | [1] | |||
| Structure |
![]() |
|||||
| 3D MOL | 2D MOL | |||||
| Pharmaceutical Properties | Molecular Weight | 150.13 | Topological Polar Surface Area | 90.2 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| Cross-matching ID | ||||||
| The Predicted Metabolic Roadmap of This Drug | |||||
|---|---|---|---|---|---|
| The Full List of Predicted Drug Metabolites (PDM) of This Drug | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.


